title: Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients.
abstract: BACKGROUND
  Iron deficiency anemia (IDA) is a common finding in patients after bariatric surgery. The cause is multifactorial including reduced oral iron intake and malabsorption. While many patients can be managed with oral supplements, parenteral iron may be needed to restore and maintain iron stores.
  
  
  METHODS
  Subjects who had previous bariatric surgery and had participated in phase 3 industry-sponsored clinical trials designed to assess the safety and/or efficacy of intravenous (IV) ferric carboxymaltose (FCM) were retrospectively selected from the databases of each of these studies. Demographic data, efficacy measures [hemoglobin, ferritin, and transferrin saturation (TSAT)], and adverse events were compared between FCM and other agents utilized as comparators in the trials.
  
  
  RESULTS
  Two hundred eighty-one subjects from the intention to treat (ITT) population were included (mean age 49 years, BMI 33 kg/m(2), including 253 females). FCM had similar or improved efficacy (p < 0.05) in terms of increasing hemoglobin, ferritin, and TSAT values when compared to other iron products used as standard of care for IDA. The incidence of adverse events in the FCM patients (n = 123) versus patients receiving any IV iron (n = 126) was 61 and 56.3 %, respectively. The adverse events were similar in both groups with the exception of a transient decrease in serum phosphate which was observed more frequently in the FCM group.
  
  
  CONCLUSIONS
  These data in post-bariatric surgery IDA patients suggest that FCM is a safe and effective alternative to existing iron products permitting higher and thus less frequent individual doses.
authors.affiliation: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave., Albany, NY 12208, USA. margaret.malone@acphs.edu
authors.forename: Margaret
authors.initials: M
authors.lastname: Malone
authors.forename: Charles
authors.initials: C
authors.lastname: Barish
authors.forename: Andy
authors.initials: A
authors.lastname: He
authors.forename: David
authors.initials: D
authors.lastname: Bregman
mesh_terms: D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D050110:Bariatric Surgery / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins; D006801:Humans; D007262:Infusions, Intravenous; D019266:Iron, Dietary / Q000627:therapeutic use; D008286:Malabsorption Syndromes / Q000097:blood / Q000209:etiology / Q000628:therapy*; D008297:Male; D008320:Maltose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood / Q000150:complications / Q000601:surgery*; D010288:Parenteral Nutrition / Q000379:methods; D011183:Postoperative Complications / Q000097:blood / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D014168:Transferrin; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D015415:Biomarkers; D005290:Ferric Compounds; D006397:Hematinics; D006454:Hemoglobins; D019266:Iron, Dietary; D014168:Transferrin; C522335:ferric carboxymaltose; D008320:Maltose; D005293:Ferritins
references.citation: Obes Surg. 1999 Feb;9(1):17-21
references.pmid: 10065575
references.citation: Obesity (Silver Spring). 2010 Oct;18(10):2010-6
references.pmid: 20075851
references.citation: Endocr Pract. 2008 Apr;14(3):318-36
references.pmid: 18463039
references.citation: Surg Obes Relat Dis. 2011 Mar-Apr;7(2):151-6
references.pmid: 20702143
references.citation: J Am Soc Nephrol. 2007 Feb;18(2):394-400
references.pmid: 17229910
references.citation: Obes Surg. 2008 Mar;18(3):288-93
references.pmid: 18214631
references.citation: Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78
references.pmid: 17666600
references.citation: Am J Clin Nutr. 2009 Sep;90(3):527-32
references.pmid: 19625680
references.citation: Obes Surg. 2010 Feb;20(2):181-7
references.pmid: 19705207
references.citation: Drugs. 2009;69(6):739-56
references.pmid: 19405553
references.citation: Anemia. 2012;2012:172104
references.pmid: 22997572
references.citation: J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7
references.pmid: 19366850
references.citation: J Gastrointest Surg. 1998 Sep-Oct;2(5):436-42
references.pmid: 9843603
references.citation: Obes Surg. 2002 Aug;12(4):551-8
references.pmid: 12194550
references.citation: Obes Rev. 2012 Feb;13(2):150-61
references.pmid: 21981048
references.citation: J Gastrointest Surg. 2002 Mar-Apr;6(2):195-203; discussion 204-5
references.pmid: 11992805
references.citation: Obes Surg. 2008 Aug;18(8):1028-34
references.pmid: 18461424
references.citation: Surg Obes Relat Dis. 2013 Jan-Feb;9(1):129-32
references.pmid: 22867554